Altered Mentation and Confusion in Brain Metastases

Differential Diagnosis Approach

Brain metastases directly cause cognitive decline in up to 90% of patients through mass effect, edema, or leptomeningeal spread, requiring initial evaluation with MRI brain and spine with and without contrast to assess for progression of metastases, new lesions, or leptomeningeal enhancement 1, 2, 4, 5
The American Society of Clinical Oncology recommends ruling out direct tumor effects, metabolic derangements, infection, and seizures before attributing symptoms to paraneoplastic syndrome, particularly in patients with coexisting liver disease 1, 2, 3
The initial evaluation should include assessment for increased intracranial pressure and mass effect requiring urgent intervention, as well as evaluation for leptomeningeal metastases, which present with mental changes, radicular signs, and gait difficulties 1, 4, 6

Given the history of liver disease, hepatic encephalopathy is a diagnosis of exclusion that must be actively investigated, with checks for precipitating factors such as infections, GI bleeding, electrolyte disorders, acute kidney injury, dehydration, constipation, and sedative medications 7
The European Association for the Study of the Liver recommends avoiding routine ammonia testing and starting empiric lactulose if hepatic encephalopathy is suspected, titrating to 2-3 soft stools daily 7

Metabolic derangements and infections are common, treatable causes of confusion in cancer patients with liver disease, with electrolyte abnormalities, infections, and medication review being crucial steps in the diagnostic process 3, 8
The National Comprehensive Cancer Network recommends checking for electrolyte abnormalities, such as hyponatremia, and evaluating for infections, which are contributory factors in 46% of confused cancer patients 3

Electroencephalogram is essential to exclude non-convulsive seizures in patients with encephalopathy and brain metastases, although anti-seizure medications should not be used prophylactically in patients with brain metastases who have not had seizures 1, 2, 8

Paraneoplastic neurologic syndromes should be considered only after ruling out other causes, with key features including paraneoplastic encephalitis presenting with confusion, altered behavior, short-term memory loss, and seizure-like activity 1, 2
The American Academy of Neurology recommends diagnosis requiring CSF analysis showing lymphocytic pleocytosis and elevated protein, plus paraneoplastic antibody panel 1, 2

If brain metastases with mass effect, treatment priorities include dexamethasone 4-8 mg/day for symptomatic relief and definitive therapy with surgical resection or radiosurgery 4, 8
If hepatic encephalopathy, treatment priorities include lactulose, correction of precipitating factors, and maintenance of sodium levels >130 mmol/L 7
If paraneoplastic syndrome confirmed, treatment priorities include immediate treatment of underlying cancer and immunotherapy for antibody-mediated syndromes 1, 2